Quantcast

Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Research paper by Hiroto H Inaba, Jie J Yang, Jianmin J Pan, Dennis C DC Stokes, Matthew J MJ Krasin, Ashok A Srinivasan, Christine M CM Hartford, Ching-Hon CH Pui, Wing W Leung

Indexed on: 27 Feb '10Published on: 27 Feb '10Published in: Cancer



Abstract

The number of long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasing; however, few studies have addressed their long-term pulmonary function.The authors examined 660 baseline and follow-up pulmonary function tests in 89 long-term survivors of pediatric hematologic malignancies and allo-HSCT.At least 1 abnormal lung parameter was seen in 40.4% of baseline tests and developed in 64% of post-allo-HSCT tests (median follow-up: 8.9 years). Abnormal baseline values in ratio of forced expiratory volume in 1 second and forced vital capacity (FEV(1)/FVC), FEV(1), residual volume (RV), functional residual capacity (FRC), and FVC were associated with abnormal post-allo-HSCT values. The following pulmonary function values declined significantly with time: FEV(1)/FVC, forced mid-expiratory flow (FEF(25%-75%)), total lung capacity (TLC), diffusion capacity corrected for hemoglobin (DLCO(corr)), RV, FRC, and RV/TLC. Older age at the time of allo-HSCT was associated with lower FEV(1)/FVC, FEF(25%-75%), and DLCO(corr) and higher RV/TLC. Patients who experienced respiratory events within 1 year post-allo-HSCT had lower FEV(1) and FVC values and higher RV/TLC from their baseline pulmonary function tests. Female patients had reduced FVC, TLC, and RV values but higher FEV(1)/FVC. Pulmonary dysfunction was also associated with high-risk hematological malignancies and peripheral blood HSC product.Abnormal pulmonary functions in allo-HSCT survivors are prevalent, which underscore the need for risk-adapted continual monitoring and improved preventive and management strategies.